View Item 

Show simple item record

Meta‐analysis: the impact of oral anti‐viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B
dc.contributor.authorSingal, A. K.en_US
dc.contributor.authorSalameh, H.en_US
dc.contributor.authorKuo, Y.‐f.en_US
dc.contributor.authorFontana, R. J.en_US
dc.date.accessioned2013-06-18T18:33:29Z
dc.date.available2014-09-02T14:12:52Zen_US
dc.date.issued2013-07en_US
dc.identifier.citationSingal, A. K.; Salameh, H.; Kuo, Y.‐f. ; Fontana, R. J. (2013). "Metaâ analysis: the impact of oral antiâ viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B." Alimentary Pharmacology & Therapeutics 38(2): 98-106. <http://hdl.handle.net/2027.42/98397>en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/98397
dc.publisherWiley Periodicals, Inc.en_US
dc.titleMeta‐analysis: the impact of oral anti‐viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis Ben_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid23713520en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/98397/1/apt12344.pdf
dc.identifier.doi10.1111/apt.12344en_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceLiaw YF, Leung N, Kao JH, et al. Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263 – 83.en_US
dc.identifier.citedreferenceHeathcote EJ, Marcellin P, Buti M, et al. Three‐year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132 – 43.en_US
dc.identifier.citedreferencePapatheodoridis GV, Manolakopoulos S, Touloumi G, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg‐negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut 2011; 60: 1109 – 16.en_US
dc.identifier.citedreferenceSherman M, Bruix J, Porayko M, Tran T. Screening for hepatocellular carcinoma: the rationale for the AASLD recommendations. Hepatology 2012; 56: 793 – 6.en_US
dc.identifier.citedreferenceBruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2012; 53: 1020 – 2.en_US
dc.identifier.citedreferenceUlm K. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR). Am J Epidemiol 1990; 131: 373 – 5.en_US
dc.identifier.citedreferenceHosaka T, Suzuki F, Kobayashi M, et al. Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2012 [Epub ahead of print].en_US
dc.identifier.citedreferenceKoklu S, Tuna Y, Gulsen MT, et al. Long‐term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus‐related cirrhosis. Clin Gastroenterol Hepatol 2013; 11: 88 – 94.en_US
dc.identifier.citedreferenceFattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335 – 52.en_US
dc.identifier.citedreferenceSimonetti RG, Camma C, Fiorello F, Politi F, D'Amico G, Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 1991; 36: 962 – 72.en_US
dc.identifier.citedreferenceYang JD, Kim WR, Coelho R, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9: 64 – 70.en_US
dc.identifier.citedreferenceBeasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942 – 56.en_US
dc.identifier.citedreferenceFattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP study group on hepatitis B virus and cirrhosis. Hepatology 1995; 21: 77 – 82.en_US
dc.identifier.citedreferenceChen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65 – 73.en_US
dc.identifier.citedreferenceFattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long‐term outcome of hepatitis B e antigen‐positive patients with compensated cirrhosis treated with interferon alfa. European concerted action on viral hepatitis (EUROHEP). Hepatology 1997; 26: 1338 – 42.en_US
dc.identifier.citedreferenceFattovich G, Giustina G, Sanchez‐Tapias J, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol 1998; 93: 896 – 900.en_US
dc.identifier.citedreferenceFattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002; 97: 2886 – 95.en_US
dc.identifier.citedreferenceEl‐Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264 – 73.en_US
dc.identifier.citedreferenceLai CL, Yuen MF. Prevention of hepatitis B virus‐related hepatocellular carcinoma with antiviral therapy. Hepatology 2013; 57: 399 – 408.en_US
dc.identifier.citedreferenceYang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168 – 74.en_US
dc.identifier.citedreferenceLok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661 – 2.en_US
dc.identifier.citedreferenceLiaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521 – 31.en_US
dc.identifier.citedreferenceSingal AK, Fontana RJ. Meta‐analysis: oral anti‐viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther 2012; 35: 674 – 89.en_US
dc.identifier.citedreferencePapatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53: 348 – 56.en_US
dc.identifier.citedreferenceKobashi H, Miyake Y, Ikeda F, et al. Long‐term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. Hepatol Res 2011; 41: 405 – 16.en_US
dc.identifier.citedreferenceInoue J, Ueno Y, Wakui Y, et al. Four‐year study of lamivudine and adefovir combination therapy in lamivudine‐resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern. J Viral Hepat 2011; 18: 206 – 15.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt12344.pdf
Size:
226.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.